Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 7Colorectal Neoplasms 6Neoplasms 4Neoplasm Metastasis 4Esophageal Neoplasms 4Pancreatic Neoplasms 3Gallbladder Neoplasms 3Breast Neoplasms 3Urinary Bladder Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Bile Duct Neoplasms 2Prostatic Neoplasms 1Oesophagogastric Cancer 1Head and Neck Neoplasms 1HER2 Positive Esophagogastric Cancer 1Gastrointestinal Neoplasms 1GastroEsophageal Cancer 1Esophageal Squamous Cell Carcinoma 1Dysgerminoma 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms, Male 1

Interventions

Radiotherapy 1Oxaliplatin 1Lapatinib 1Fluorouracil 1Combined Modality Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2 Positive Esophagogastric Cancer × Lapatinib × Gastrointestinal × Clear all
NCT01769508 2016-06-13

Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer

SCRI Development Innovations, LLC

Phase 2 Terminated
12 enrolled 8 charts
Gastrointestinal

HER2 Positive Esophagogastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡